Latest news
25 items- PRPureTech Health plc – Half-Year ReportStrong progress across PureTech's portfolio, with significant near-term catalysts Robust shareholder returns enabled by Founded Entity1 monetization; $100 million Tender Offer and $50 million buyback completed Strong balance sheet with expected operational runway for at least three years Company to host a webcast and conference call today at 9:00am EDT / 2:00pm BST PureTech Health plc (NASDAQ:PRTC, LSE: PRTC))) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announces its half-yearly results for the six months ended June 30, 2024. The following information will be filed on Form 6-K w
- SECSEC Form 15-12G filed by Akili Inc.15-12G - Akili, Inc. (0001850266) (Filer)
- SECSEC Form EFFECT filed by Akili Inc.EFFECT - Akili, Inc. (0001850266) (Filer)
- 13D/GAmendment: SEC Form SC 13D/A filed by Akili Inc.SC 13D/A - Akili, Inc. (0001850266) (Subject)
- INSIDERSEC Form 4 filed by Large owner Puretech Health Plc4 - Akili, Inc. (0001850266) (Issuer)
- INSIDERSEC Form 4 filed by Large owner Palihapitiya Chamath4 - Akili, Inc. (0001850266) (Issuer)
- 13D/GAmendment: SEC Form SC 13D/A filed by Akili Inc.SC 13D/A - Akili, Inc. (0001850266) (Subject)
- 13D/GAmendment: SEC Form SC 13G/A filed by Akili Inc.SC 13G/A - Akili, Inc. (0001850266) (Subject)
- INSIDERSEC Form 4 filed by Large owner Temasek Holdings (Private) Ltd4 - Akili, Inc. (0001850266) (Issuer)
- INSIDERPresident & CEO Franklin Matthew returned 33,000 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Akili, Inc. (0001850266) (Issuer)
- INSIDERChief Legal Officer Studer Jacqueline returned 92,869 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Akili, Inc. (0001850266) (Issuer)
- INSIDERDirector Martucci Walter Edward Ii returned 99,548 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Akili, Inc. (0001850266) (Issuer)
- INSIDERSEC Form 4 filed by Director Spinale John4 - Akili, Inc. (0001850266) (Issuer)
- INSIDERDirector Gazzaley Adam closing all direct ownership in the company (SEC Form 4)4 - Akili, Inc. (0001850266) (Issuer)
- SECSEC Form S-8 POS filed by Akili Inc.S-8 POS - Akili, Inc. (0001850266) (Filer)
- SECSEC Form S-8 POS filed by Akili Inc.S-8 POS - Akili, Inc. (0001850266) (Filer)
- SECSEC Form POS AM filed by Akili Inc.POS AM - Akili, Inc. (0001850266) (Filer)
- SECAkili Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits8-K - Akili, Inc. (0001850266) (Filer)
- SECAmendment: SEC Form SC 14D9/A filed by Akili Inc.SC 14D9/A - Akili, Inc. (0001850266) (Subject)
- SECSEC Form 25-NSE filed by Akili Inc.25-NSE - Akili, Inc. (0001850266) (Subject)
- PRVirtual Therapeutics Announces Results of Tender Offer to Acquire Akili InteractiveVirtual Therapeutics, a company focused on improving mental health at scale using engaging, immersive games ("Virtual Therapeutics"), today announced that it has successfully completed the tender offer commenced on June 3, 2024, to acquire all outstanding shares of common stock of Akili, Inc. (NASDAQ:AKLI) ("Akili") for $0.4340 per share (the "Offer Price"). The tender offer expired at one minute after 11:59 p.m. EDT on July 1, 2024 (the "Expiration Date"). As of the Expiration Date, a total of 69,674,538 shares, representing approximately 88.2% of the outstanding shares of common stock of Akili, were validly tendered and not validly withdrawn. The number of shares validly tendered in acc
- SECSEC Form 8-K filed by Akili Inc.8-K - Akili, Inc. (0001850266) (Filer)
- NEWSAkili Says EndeavorOTC Is The Only FDA-Authorized Digital Therapeutic For ADHD Available Without A PrescriptionDelivered through an engaging video game experience, EndeavorOTC is indicated to improve attention function as measured by computer-based testing in men and women with primarily inattentive or combined-type ADHD, who have a demonstrated attention issue. EndeavorOTC is Akili's second digital ADHD therapeutic product to receive FDA authorization
- NEWSAkili Reports FDA Clearance Of EndeavorOTC (AKL-T01) As An Over-the-counter Treatment For Adults With Attention-deficit/Hyperactivity Disorder
- PRAkili Announces FDA Authorization of EndeavorOTC, the First FDA Clearance of a Digital Treatment for Adults with ADHD Through a Video GameClinically proven to improve attention function, EndeavorOTCⓇ is the first and only digital therapeutic cleared by FDA as an over-the-counter treatment for adults with ADHD Akili, Inc. (NASDAQ:AKLI), a leading digital therapeutics company, today announced U.S. Food and Drug Administration (FDA) clearance of EndeavorOTCⓇ (AKL-T01) as an over-the-counter treatment for adults with attention-deficit/hyperactivity disorder (ADHD). Delivered through an engaging video game experience, EndeavorOTC is indicated to improve attention function as measured by computer-based testing in men and women with primarily inattentive or combined-type ADHD, who have a demonstrated attention issue. EndeavorOTC i
AKLI FAQ
5 questionsWhere does AKLI stock trade?
Akili Inc. (AKLI) is listed on NASDAQ.What sector and industry is AKLI in?
Akili Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did Akili Inc. go public?
Akili Inc. (AKLI) completed its IPO in 2021.What companies are similar to AKLI?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare AKLI side-by-side with any of them on Quantisnow.How can I track AKLI on Quantisnow?
Quantisnow aggregates Akili Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AKLI to receive live email and push alerts on every new disclosure.